IL160993A0 - Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof - Google Patents

Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Info

Publication number: IL160993A0
Authority: IL; Israel
Prior art keywords: diagnostic; bombesin analog; analog conjugates; therapeutic somatostatin; somatostatin
Prior art date: 2001-09-21

Application number

IL16099302A

Other languages

English (en)

Original Assignee

Univ Tulane

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2002-09-20

Publication date

2004-08-31

2002-09-20 Application filed by Univ Tulane filed Critical Univ Tulane

2004-08-31 Publication of IL160993A0 publication Critical patent/IL160993A0/xx

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Percussion Or Vibration Massage (AREA)

IL16099302A 2001-09-21 2002-09-20 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof IL160993A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32385101P	2001-09-21	2001-09-21
PCT/US2002/030143 WO2003028527A2 (fr)	2001-09-21	2002-09-20	Conjugues d'analogues de somatostatine ou de bombesine a vocation diagnostique ou therapeutique, et utilisations correspondantes

Publications (1)

Publication Number	Publication Date
IL160993A0 true IL160993A0 (en)	2004-08-31

Family

ID=23260992

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16099302A IL160993A0 (en)	2001-09-21	2002-09-20	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
IL160993A IL160993A (en)	2001-09-21	2004-03-21	Diagnostic or therapeutic couplings that are analogues of somatostatin or bombsin, uses for them and methods of manufacturing a medicinal product

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL160993A IL160993A (en)	2001-09-21	2004-03-21	Diagnostic or therapeutic couplings that are analogues of somatostatin or bombsin, uses for them and methods of manufacturing a medicinal product

Country Status (16)

Country	Link
US (1)	US7326685B2 (fr)
EP (1)	EP1435826A4 (fr)
JP (1)	JP4799820B2 (fr)
KR (1)	KR20040047846A (fr)
CN (1)	CN1589151A (fr)
AU (1)	AU2002341792B2 (fr)
BR (1)	BR0212897A (fr)
CA (1)	CA2461099A1 (fr)
IL (2)	IL160993A0 (fr)
IS (1)	IS7189A (fr)
MX (1)	MXPA04002621A (fr)
NO (1)	NO20041186L (fr)
NZ (1)	NZ532204A (fr)
PL (1)	PL369336A1 (fr)
WO (1)	WO2003028527A2 (fr)
ZA (1)	ZA200402698B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6721705B2 (en) *	2000-02-04	2004-04-13	Webley Systems, Inc.	Robust voice browser system and voice activated device controller
US7771727B2 (en) *	2002-03-01	2010-08-10	The Administrators Of The Tulane Educational Fund	Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US8060626B2 (en) *	2008-09-22	2011-11-15	Sony Computer Entertainment America Llc.	Method for host selection based on discovered NAT type
US7977049B2 (en) *	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CN101791409A (zh) *	2003-04-22	2010-08-04	研究及应用科学协会股份有限公司	肽载体
JP2007530417A (ja) *	2003-07-01	2007-11-01	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	細胞及び生物の寿命及びストレス応答を操作するための組成物
US20060025337A1 (en) *	2003-07-01	2006-02-02	President And Fellows Of Harvard College	Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en)	2003-12-29	2005-08-04	President And Fellows Of Harvard College	Compositions for treating or preventing obesity and insulin resistance disorders
US20050255045A1 (en) *	2004-05-13	2005-11-17	Woltering Eugene A	Surgical marking composition and method
CA2467321A1 (fr)	2004-05-14	2005-11-14	Paul J. Santerre	Agents de couplage polymeres et polymeres ayant une activite pharmaceutique produits a partir de ceux-ci
EP1744787A4 (fr) *	2004-05-14	2011-04-06	Interface Biologics Inc	Agents de couplage polymeres et polymeres pharmaceutiquement actifs obtenus a partir desdits agents
US20060084085A1 (en) *	2004-06-16	2006-04-20	Sinclair David A	Methods and compositions for modulating Bax-mediated apoptosis
US20060014705A1 (en) *	2004-06-30	2006-01-19	Howitz Konrad T	Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (fr) *	2005-06-14	2006-12-28	President And Fellows Of Harvard College	Amelioration de la performance cognitive avec des activateurs de sirtuine
EP1890677A4 (fr) *	2005-06-16	2013-01-30	Myriad Genetics Inc	Compositions pharmaceutiques et leur utilisation
US8735177B2 (en)	2006-02-23	2014-05-27	Adeka Corporation	Diagnostic marker
DE102006035083A1 (de) *	2006-07-28	2008-01-31	medac Gesellschaft für klinische Spezialgeräte mbH	Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
US8691761B2 (en) *	2006-10-16	2014-04-08	Jean E. F. Rivier	Somatostatin receptor 2 antagonists
EP2383289B1 (fr)	2006-10-16	2014-10-08	The Salk Institute for Biological Studies	Antagonistes de la somatostatine sélectifs du récepteur SSTR2
NZ577039A (en) *	2006-10-20	2011-11-25	Ipsen Pharma Sas	Peptide-cytotoxic conjugates comprising campthoecin and a somatostatin
NZ580866A (en) *	2007-04-10	2011-02-25	Myriad Pharmaceuticals Inc	Method of treating brain cancer
NZ580868A (en) *	2007-04-10	2011-07-29	Myriad Pharmaceuticals Inc	Dosages and methods for the treatment of cancer
NZ580869A (en) *	2007-04-10	2011-02-25	Myriad Pharmaceuticals Inc	Methods for treating cancer
WO2008124828A1 (fr) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Méthodes de traitement de troubles réagissant à une interruption vasculaire
EP2144886A4 (fr) *	2007-04-10	2012-10-03	Myrexis Inc	Méthode de traitement du mélanome
WO2012112792A2 (fr)	2011-02-17	2012-08-23	The Administrators Of The Tulane Educational Fund	Compositions multicomposants et leurs utilisations
CN105283201B (zh)	2013-03-14	2019-08-02	斯克利普斯研究所	靶向剂抗体偶联物及其用途
KR102891788B1 (ko)	2016-02-04	2025-11-26	더 스크립스 리서치 인스티튜트	인간화 항-cd3 항체, 접합체 및 이의 용도
KR20250158818A (ko)	2016-02-09	2025-11-06	씨디알디 벤쳐스 인코포레이티드	소마토스타틴 수용체 길항제 화합물 및 이의 이용 방법
CN109311910B (zh)	2016-03-24	2022-02-01	杜兰教育基金委员会	他克莫司偶联物、其组合物、及其用途
EP3717019A4 (fr) *	2017-11-28	2021-09-22	Board of Regents of the University of Nebraska	Produits radiopharmaceutiques et leurs procédés d'utilisation
CN111971292B (zh)	2018-02-02	2024-12-13	波纹疗法公司	包含类固醇二聚体的玻璃制剂及其用途
JP7368854B2 (ja) *	2018-03-15	2023-10-25	国立大学法人大阪大学	２１１Ａｔ標識化アミノ酸誘導体を含む医薬組成物及びその製造方法
WO2020154815A1 (fr)	2019-02-01	2020-08-06	Ripple Therapeutics Corporation	Formes cristallines de dimères de dexaméthasone et leurs utilisations
US12509469B2 (en)	2019-08-07	2025-12-30	Ripple Therapeutics Corporation	Compositions and methods for the treatment of pain and dependence disorders
WO2021220061A2 (fr)	2020-05-01	2021-11-04	Ripple Therapeutics Corporation	Compositions hétérodimères et méthodes pour le traitement de troubles oculaires

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en)	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en) *	1987-11-18	1991-12-17	Administrators Of The Tulane Educational Fund	Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en)	1988-12-05	1998-05-19	Novartis Ag	Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en)	1989-04-26	1997-05-27	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
DK0436005T3 (da)	1989-07-20	1995-07-03	Sandoz Ltd	Mærkede polypeptidderivater
DK0450480T3 (da) *	1990-04-06	1995-08-14	Univ Tulane	Somatostatinaloger
US5443815A (en)	1991-11-27	1995-08-22	Diatech, Inc.	Technetium-99m labeled peptides for imaging
US5411943A (en)	1992-02-25	1995-05-02	Biomeasure, Inc.	Hepatoma treatment with somatostatin analogs
US5620675A (en) *	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5597894A (en) *	1995-06-05	1997-01-28	The Louisiana State University Medical Center Foundation	Multi-tyrosinated somatostatin analogs
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) *	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5708135A (en)	1995-09-29	1998-01-13	Biomeasure Incorporated	Cyclic peptide analogs of somatostatin
US5750499A (en)	1995-10-18	1998-05-12	The Salk Institute For Biological Studies	Receptor-selective somatostatin analogs
US5843903A (en)	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US6156725A (en) *	1996-08-16	2000-12-05	National Institute Of Immunology	Drug for the treatment of cancer
EP0977579B1 (fr)	1997-04-22	2009-03-11	Curator Of The University Of Missouri	Conjugues de peptides avides d'un recepteur de la gastrine
AU4267700A (en) *	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
BR0210915A (pt) *	2001-06-08	2004-06-08	Sod Conseils Rech Applic	Análogos quiméricos de somatostatina-dopamina

2002
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/fr not_active Ceased
- 2002-09-20 CA CA002461099A patent/CA2461099A1/fr not_active Abandoned
- 2002-09-20 EP EP02775944A patent/EP1435826A4/fr not_active Withdrawn
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown

Also Published As

Publication number	Publication date
PL369336A1 (en)	2005-04-18
NZ532204A (en)	2006-04-28
IL160993A (en)	2011-04-28
WO2003028527A3 (fr)	2003-10-30
EP1435826A2 (fr)	2004-07-14
IS7189A (is)	2004-03-19
BR0212897A (pt)	2004-08-24
WO2003028527A8 (fr)	2004-04-15
MXPA04002621A (es)	2004-07-08
ZA200402698B (en)	2005-04-25
US7326685B2 (en)	2008-02-05
NO20041186L (no)	2004-05-05
EP1435826A4 (fr)	2009-07-15
WO2003028527A2 (fr)	2003-04-10
AU2002341792B2 (en)	2007-09-06
US20050070470A1 (en)	2005-03-31
CA2461099A1 (fr)	2003-04-10
JP2005505580A (ja)	2005-02-24
CN1589151A (zh)	2005-03-02
JP4799820B2 (ja)	2011-10-26
KR20040047846A (ko)	2004-06-05

Publication	Publication Date	Title
IL160993A0 (en)	2004-08-31	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
IL195076A0 (en)	2011-08-01	Improved skin substitutes and uses thereof
AU1328502A (en)	2002-05-15	Novel targeted compositions for diagnostic and therapeutic use
EP1572741A4 (fr)	2006-09-27	Agents diagnostiques et therapeutiques
IL161291A0 (en)	2004-09-27	Human 3 relaxin
AU2002303261A8 (en)	2006-11-02	Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2002-10-21	Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en)	2002-10-21	Gene scc-112 and diagnostic and therapeutic uses thereof
SI1462455T1 (sl)	2013-09-30	Ser-Ser-Ser-Arg Peptid in zdravilna uporaba le-tega
HUP0600436A2 (en)	2006-09-28	Catheter composition and uses thereof
GB0119025D0 (en)	2001-09-26	Compounds and their therapeutic use
GB0115780D0 (en)	2001-08-22	Therapeutic molecules and uses thereof
AU2002360790A8 (en)	2003-06-17	Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
AU2002303262A1 (en)	2002-10-21	Gene shinc-1 and diagnostic and therapeutic uses thereof
HK1070255A (en)	2005-06-17	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
IL153653A0 (en)	2003-07-06	Novel therapeutic molecular variants and uses thereof
GB2376943B (en)	2005-03-16	Compounds and their therapeutic use
GB0410147D0 (en)	2004-06-09	Human angiomotin-like protein 1
AU2003235665A8 (en)	2003-07-30	Diagnostic and therapeutic uses of topors
GB0112237D0 (en)	2001-07-11	Compounds and their therapeutic use
AUPR556601A0 (en)	2001-07-12	Therapeutic and diagnostic molecules - II
AU2002367139A8 (en)	2003-07-15	Human netrin receptor and uses thereof
GB0103620D0 (en)	2001-03-28	Sterile composition and its preparation
AU2001249688A1 (en)	2001-10-15	Human leucine-rich repeat family member and uses thereof
GB0122246D0 (en)	2001-11-07	Immunotoxins and their therapeutic application